The U.S. Food and Drug Administration approved the drug rilonacept to treat a group of rare diseases causing rash, fever, chills and joint pain.
Rilonacept, marketed under the name Arcalyst by Regeneron Pharmaceuticals, received marketing approval for the treatment of Cyropyrin-Associated Periodic Syndromes, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome in adults and children ages 12 and older.
The familial cold syndrome is an "orphan" hereditary disease affecting only about 300 people in the United States, 90 percent of whom can trace their ancestry to a single person who came to America in the 1600s, the University of California's San Diego School of Medicine said Wednesday in a news release. Symptoms can be triggered at any time by exposure to cold temperatures, stress or exercise,
The drug is based on a discovery by Dr. Hal Hoffman, a professor at the medical school, who identified the genetic basis of the disease as a mutation that causes alterations in the protein cryopyrin.
Copyright 2008 by United Press International
Related stories:
Research links genetic mutations to lupus
A gene discovered by scientists at Wake Forest University School of Medicine has been linked to lupus and related autoimmune diseases. The finding, reported in the current issue of
Nature Genetics, is the latest in a series of revelations that shed new light on what goes wrong in human cells to cause the diseases.
Think herbal supplements are safe? Think again, book by SLU doctor says
People are mixing supplements, herbs and over-the-counter medications and prescription drugs to cure themselves of ills, unaware that they could be making themselves sicker, says George Grossberg, M.D., director of the division of geriatric psychiatry at Saint Louis University.
Quitting smoking may be harder if mom smoked during pregnancy
Quitting smoking may be more difficult for individuals whose mothers smoked during pregnancy, according to animal research conducted by Duke University Medical Center researchers.
Study finds parents use cough medicines on under-2s despite the warnings
More than 40 per cent of parents have used cough medicine for children younger than two – even though it is not recommended, nor proven effective for children in this age group, an Australia-first study has found.
Effect of mutant p53 stability on tumorigenesis and drug design
In the May 15th issue of G&D, Dr. Guillermina Lozano (MD Anderson Cancer Center) and colleagues reveal how the stabilization of a mutated form of p53 affects oncogenesis, and lends startling new insight into the potential pitfalls of using Mdm2 inhibitors for cancer therapy.
Research sheds new light on heroin addiction
Researchers from the Howard Florey Institute in Melbourne have identified a factor that may contribute towards the development of heroin addiction by manipulating the adenosine A2A receptor, which plays a major role in the brain’s ‘reward pathway’.
Human aging gene found in flies
Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have found a fast and effective way to investigate important aspects of human ageing. Working at the University of Oxford and The Open University, Dr Lynne Cox and Dr Robert Saunders have discovered a gene in fruit flies that means flies can now be used to study the effects ageing has on DNA.
Chantix recommended to quit smoking despite safety concerns
(AP) -- The federal government's new advice to doctors for helping smokers quit recommends the drug Chantix, which has recently been linked with depression and suicidal behavior. The new guidelines mention the psychiatric risks but also say the popular Pfizer Inc. drug is the most effective at helping people get off cigarettes.